Pharmaceutical Technology9 天
Telisotuzumab adizutecan by AbbVie for Renal Cell Carcinoma: Likelihood of Approval
Telisotuzumab adizutecan is under clinical development by AbbVie and currently in Phase I for Renal Cell Carcinoma.
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and ...
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and ...
Targeted Oncology3 天
Adjuvant Pembrolizumab Keeps Survival Benefit in RCC
Updated overall survival data from KEYNOTE-564 showed adjuvant pembrolizumab benefits in clear cell renal cell carcinoma, but ...
Pharmaceutical Technology9 天
BGB-10188 by BeiGene for Renal Cell Carcinoma: Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Renal Cell Carcinoma have a 29% phase transition ...